0025sek
29,4 %
Date:2025-05-14Time:17:29:57Latest report:Q4-2024List:First NorthTicker:SCOL
Market Cap:6 msekEnterprise Value:-13 msekNet Sales:- mdkkEarnings:-36,7 mdkkEmployees:0ISIN:DK0061031895

Ratios

10-year key figure history for Scandion Oncology turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Scandion Oncology with index and moving average MA50 and MA200.

Stockprice:0,025
MA50:0,01
MA200:0,08
Price/MA200:-69,2 %
RSI (14):72,2
Price/MA50:87,2 %

Description

Scandion Oncology is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has been used in certain standard cancer treatments during preclinical studies. The company was founded in 2017 and is headquartered in Copenhagen, Denmark.

Biotechnology